G
GNLX
vs
S&P 500

Over the past 12 months, GNLX has significantly outperformed S&P 500, delivering a return of +52% compared to the S&P 500's +13% growth.
Stocks Performance
GNLX vs S&P 500
Performance Gap
GNLX vs S&P 500
Performance By Year
GNLX vs S&P 500
Genelux Corp
Glance View
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 15 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The firm is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.